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Candida albicansAbstract A new series of hydrazide derivatives were synthesized, characterized, and biologically
evaluated. The reaction of 2-chloro benzo[d]thiazole 1, with ethyl 2-(piperazin-1-yl) acetate 2, led
to the formation of ethyl 2-(4-(benzo[d]thiazol-2-yl)piperazin-1-yl)acetate 3. The reaction of com-
pound 3 with excess amount of hydrazine hydrate gave 2-(4-(benzo[d]thiazol-2-yl) piperazin-1-yl)
acetohydrazide 4. Hydrazide derivatives 5(a–j) were prepared by the reaction of compound 4 with
the appropriate acid chloride. The in vitro antibacterial activity of compounds 3, 4, 5a, and 5b were
screened against Staphylococcus aureus, Escherichia coli, and Candida albicans bacteria, no activity
has been witnessed.
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Since the 1990s, various pharmacological investigations of
newly synthesized benzothiazoles demonstrated interesting
pharmacological activities and led to the development of new
medications for treating diseases. They were studied
extensively for their antiallergic (Ban et al., 1998), anti-inﬂam-
matory (Ban et al., 1998; Papadopoulou et al., 2005),
antitumor (Chung et al., 2004; Mc Fadyen et al., 2004;Yoshida et al., 2005; Starcevic et al., 2006), and analgesic activ-
ities (Baell et al., 2002; Westway et al., 2008). Apart from the
above mentioned activities, a benzothiazole derivative, 1,2-
(4-amino-3-methylphenyl)-5-ﬂuorobenzthiazole (Fig. 1), act-
ing through a novel mechanism, has entered the clinical trial
phase I in UK. It shows high sensitivity toward the tumor cells
by acting through aryl hydrocarbon receptor (AhR) signaling
pathway. The activation of AhR pathway in sensitive tumor
cells leads to the induction of the microsomal enzyme
CYP1A1. This converts the drug into highly reactive metabo-
lites that form adducts with DNA causing cell death
(Bradshaw and Westwell, 2004). Further, the combination of
urea and thiourea derivatives with benzothiazoles have pro-
duced DNA topoisomerase (Esteves-Souza et al., 2006; Choi
et al., 2006). Recently, Racane et al. (2001) have described
the synthesis of bis-disubstituted amidino benzothiazoles as
potential anti HIV agents. Therefore, various benzothiazole
Figure 1 2-(4-Amino-3-methylphenyl)-5-ﬂuorobenzthiazole.
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maceutical uses and play a vital role in the synthesis of fused
heterocyclic systems. In continuation of our research on the
synthesis and biological evaluation of benzothiazole analogs
(Al-Soud et al., 2007, 2008a,b, 2010), we report here the
synthesis of a new series of N0-(2-(4-(benzo[d]thiazol-2-yl)pip-
erazin derivatives.
2. Results and discussion
Recently, we have prepared some new benzothiazole deriva-
tives as anti-HIV and -tumor agents (Al-Soud et al., 2010).
Our continued efforts in the preparation of such compounds
carrying various groups might lead to biologically active can-
didates. Compounds 5(a–j) were synthesized according to the
route described in Scheme 1. Compound 3 was prepared from
the reaction of 2-chloro benzo[d]thiazole 1, with ethyl
2-(piperazin-1-yl) acetate 2, using ethanol as a solvent and
sodium bicarbonate as a base. 2-(4-(Benzo[d]thiazol-2-yl)pip-
erazin-1-yl) acetohydrazide 4 was prepared, via the conven-
tional method, from the reaction of compound 3 with an
excess amount of hydrazine hydrate using ethanol as a sol-
vent. After workup, compound 4 was obtained as a colorless
crystalline solid in 79% yield. Hydrazide derivatives 5(a–j)
were prepared by the reaction of compound 4 with the
appropriate acid chloride (benzoyl-, 3-methoxybenzoyl-,
thiophene-2-carbonyl-, acetyl-, 2-chloropyridine-3-carbonyl-,
pyrrolidine-2-carbonyl-, piperidine-4-carbonyl-, furan-2-
carbonyl-, 2-methylbenzoyl-, and benzo[d]dioxole-5-carbonyl
chloride) (Ban et al., 1998; Chung et al., 2004), in the pres-Scheme 1 Reagents and conditions: (a) EtOH, Nence of Et3N as a base, using dioxane as a solvent under re-
ﬂux for 3–6 days. After workup of the reaction, compounds
5(a–j) were isolated and puriﬁed. In a parallel way, com-
pounds 5(a–j) were prepared using the microwave assisted
method, which was found to be a more efﬁcient heating
method, giving higher yields, higher purity, and in much
shorter reaction time (30 min).
The 1H NMR and 13C NMR spectra of all prepared com-
pounds are in total agreement with the suggested structures;
DEPT experiments were employed to differentiate secondary
and quaternary carbons from primary and tertiary carbons.
Additional support of the proposed structures comes from li-
quid chromatography-mass spectral data; mass spectra of the
prepared compounds showed the correct molecular ions,
(M+), as suggested by their molecular formulas. The 1H
NMR of compound 3 showed piperazine ring protons reso-
nated as two broad singlets in the range of 2.67–3.65 ppm.
The CH2 protons of the methane group appeared as a sharp
signal at 3.23 ppm. In 1H NMR spectrum of compound 4, pro-
tons of the piperazine ring resonated as two broad signals in
the range of 2.56–3.85 ppm. The CH2 protons of the methane
group appeared as a sharp signal at 3.30 ppm. The protons of
the hydrazide moiety appeared as two broad signals at
3.89 ppm (NH2) and 8.11 ppm (NH). The
1H NMR of com-
pounds 5(a–j) showed similar patterns of aromatic H-atoms
which appeared in the range of 6.91–7.82 ppm, while those
of the piperazine ring resonated as two triplet signals in all
compounds at around 2.70 and 3.80 ppm. The protons of the
methane CH2 group appeared as a sharp singlet in the range
of 3.30–3.50 ppm.
The 13C NMR spectra of all compounds were characterized
(cf. Exper. Part). 13C NMR spectrum of compounds 5(a–j) are
in agreement with the proposed structures. The resonances in
the range 167.5–170.1 ppm were attributed to the carbonyl car-
bons. The carbon in the 1,3-thiazole ring (C‚N) resonated in
the range of 156.3–160.1 ppm. The piprazine ring carbons
appeared as two distinct signals, one resonated in the range
of 48.2–48.6 ppm and the second at around 52.7 ppm. TheaHCO3, reﬂux, 24 h; (b) NH2NH2ÆH2O, heat.
S928 M. Al-Talib et al.CH2 carbon (CH2C‚O) resonated at around 60.0 ppm. Other
carbons appeared in the expected region.
3. Antibacterial screening
The in vitro antibacterial activity of the prepared compounds
3, 4, 5a, and 5b were tested by using the Escherichia coli, a
Gram-negative bacteria, Staphylococcus aureus, and Candida
albicans, a Gram-positive bacteria. The MIC (minimum inhib-
itory concentration) values were determined by assaying the ef-
fect of each compound at concentrations of, 63, 125, 250, and
500 lg/mL. The results showed poor or no activity.
4. Experimental section
Chemicals were purchased from Aldrich, Janssen chemical and
Fluka, and were used without further puriﬁcation; silica gel
(60 G) was used for puriﬁcation. Melting points were deter-
mined using an electro thermal-digital melting point apparatus
and were uncorrected. Proton and carbon-13 nuclear magnetic
resonance (1H NMR and 13C NMR) spectra were determined
using an ultra shield NMP 300 and 400 MHz; Bruker spec-
trometer in deuterated chloroform (CDCl3), TMS was used
as standard, chemical shifts are reported in d values (ppm)
Mass spectra were determined by QP5050A GCMS, Shima-
dzu. Infrared spectroscopy was determined by Bruker TEN-
SOR 27 FTIR, Elemental analyses were determined at the
University of Rostock, Germany. Microwave assisted reac-
tions were done using microwave single beam (monowave
300) Anton paar, Al Al-Bayt University, Jordan.
4.1. Ethyl 2-(4-(benzo[d]thiazol-2-yl)piperazin-1-yl)acetate
(3)
To a reﬂuxed mixture solution of ethyl 2-(piperazin-1-yl) ace-
tate 2 (0.26 g, 1.5 mmol) in 20 ml ethanol, in the presence of
sodium bicarbonate (0.13 g, 1.5 mmol), solution of 2-chloro-
benzo[d]thiazole 1 (0.25 g, 1.5 mmol) in 10 mL ethanol was
added at once. After the completion of the reaction (24 h),
the solvent was evaporated, the residue was extracted with
water and 30 ml CHCl3 (10 · 3 ml), and the solvent was evap-
orated to afford compound 3. Yield: 0.34 g (77%), as yellow
crystals, mp 80–82 C (dec.). IR; mmax (KBr) cm1: 1650–
1700 (C‚O), 1540–1600 (Aromatic). 1H NMR (CDCl3):
7.54–7.01 (m, 4H); 3.65 (bs, 4H, piperazine-H); 2.67 (bs, 4H,
piperazine-H); 3.23 (s, 2H, CH2CO); 4.13 (q, 2H,
J= 3.3 Hz, CH2CH3); 1.22 (t, 3H, J= 3.3 Hz, CH2CH3).
13C NMR (CDCl3): 169.7, 168.5 (C‚O, C‚N), 152.1,
130.0, 126.1, 121.7, 120.7, 119.1, 60.9, 59.0, 52.0, 48.2, 14.2.
LC/MS m/z, calcd for C15H19N3O2 S [M+H]
+, 306; found,
306.
4.2. 2-(4-(Benzo[d]thiazol-2-yl)piperazin-1-yl)acetohydrazide
(4)
To a reﬂuxed mixture of compound 3 (0.34 g, 1.1 mmol) in
20 mL ethanol, hydrazine hydrate (0.62 g, 11.0 mmol) was
added, after the completion of the reaction (24 h), the solvent
was evaporated under vacuum to afford compound 4. Yield:
0.29 g (90%), as colorless crystals. mp 187–189 C (dec.). IR;
mmax (KBr) cm
1: 3100–3350 (NH), 1650–1700 (C‚O),1540–1600 (Aromatic). 1H NMR (CDCl3): 8.11 (bs, 1H,
NH); 7.63–7.07 (m, 4H); 3.88 (bs, 4H, piperazine-H); 2.56
(bs, 4H, piperazine-H); 3.18 (s, 2H, CH2CO); 3.89 (bs, 2H,
NH2).
13C NMR (CDCl3): 169.7 (C‚N), 169.9 (C‚O),
152.0, 130.3, 126.0, 121.1, 120.2, 119.1, 60.6, 52.3, 48.3, 14.2.
LC/MS m/z, calcd for C13H17N5O S [M+H]
+, 292; found,
292.5. General procedure for the synthesis of compound (5a–j)
Procedure A: To a reﬂuxing mixture of the acid hydrazide 4
(1.0 mmol) and triethylamine (1.0 mmol) in 20 mL dioxane, a
solution of acyl chloride (1.6 mmol) in 10 mL dioxane was
added drop wise. After the completion of the reaction (3–6)
days the reaction mixture was washed with 5% NaHCO3
and extracted with CHCl3 (10 · 3 mL), solvent was evaporated
under reduced pressure and the product was puriﬁed using a
TLC plate (ﬂuent CHCl3:ethanol (9.75:0.25), to afford color-
less to yellow powdered compounds 5(a–j).
Procedure B: A mixture of the acid hydrazide 4 (1.0 mmol),
triethylamine (1.0 mmol) and acyl chlorides (1.6 mmol) in
3–4 mL dioxane was mixed and poured into a microwave tube
and then the reaction was started at 110 C. After the comple-
tion of the reaction (30) minutes, the reaction mixture was
washed with 5% NaHCO3 and extracted with CHCl3
(3 · 3 mL), 10 mL hexane was added to the whole mixture
and then it was cooled until precipitation occurred, the precip-
itate was ﬁltered out to afford colorless to pale yellow
powdered compounds 5(a–j) in high yield.
5.1. N0-(2-(4-(Benzo[d]thiazole-2-yl)piperazin-1-yl)acetyl)-
benzohydrazide (5a)
The title compound was prepared from compound 4 (0.291 g,
1.0 mmol) and benzoyl chloride (0.226 g, 1.6 mmol) according
to the procedure A (time = 4 days). Yield: 0.091 g (23%), as a
pale yellow powder. mp 113–115 C (dec.). Procedure B
(time = 30 min): Yield: 0.319 g (81%). IR; mmax (KBr) cm
1:
3100–3250 (NH), 1650–1700 (C‚O), 1540–1600 (Aromatic).
1H NMR (CDCl3): 9.09 (bs, 1H, NH); 7.86–7.09 (m, 9H,
Ar); 9.60 (bs, 1H, NH);. 3.76 (bs, 4H, piperazine-H); 3.29 (s,
2H, CH2); 2.79 (bs, 4H, piperazine-H).
13C NMR (CDCl3):
170.0, 167.3, 162.0, 132.5, 131.2, 130.0, 129.7, 128.8, 127.2,
126.1, 121.7, 120.8, 119.2, 60.50, 52.8, 48.3. LC/MS m/z, calcd
for C20H21N5O2S [M+H]
+, 396; found, 396.
5.2. N0-(2-(4-(benzo[d]thiazol-2-yl)piperazin-1-yl)acetyl)-3-
methoxybenzohydrazide (5b)
The title compound was prepared from compound 4 (0.291 g,
1.0 mmol) and 3-methoxybenzoyl chloride (0.273 g, 1.6 mmol)
according to the procedure A (time = 3 days). Yield: 0.132 g
(31%), as a yellow powder. mp 77–80 C (dec.). Procedure B
(time = 30 min): Yield: 0.353 g (83%). IR; mmax (KBr) cm
1:
3150–3300 (NH), 1640–1700 (C‚O), 1550–1610 (Aromatic).
1H NMR (CDCl3): 9.74–9.53 (bs, 2H, NHNH); 6.92–7.62
(m, 8H, Ar); 3.81 (s, 3H, OCH3);. 3.69 (bs, 4H, piperazine-
H); 3.22 (s, 2H, CH2); 2.71 (bs, 4H, piperazine-H).
13C
NMR (CDCl3): 168.6, 168.2, 159.7, 152.6, 136.7, 132.1,
130.8, 126.1, 121.7, 120.8, 119.4, 118.9, 118.2, 115.6, 112.4,
Synthesis and biological evaluation of new benzothiazoles as antimicrobial agents S92960.5, 55.4, 52.7, 48.3. LC/MS m/z, calcd for C21H23N5O3S
[M+H]+, 427; found, 427.
5.3. N0-(2-(4-(benzo[d]thiazol-2-yl)piperazin-1-yl)acetyl)-
thiophene-2-carbohydrazide (5c)
The title compound was prepared from compound 4 (0.291 g,
1.0 mmol) and thiophene-2-carbonyl chloride (0.234 g,
1.6 mmol) according to the procedure A (time = 5 days).
Yield: 0.096 g (24%), as a white powder. mp 135–137 C
(dec.). Procedure B (time = 30 min): Yield: 0.353 g (88%).
IR; mmax (KBr) cm
1: 3150–3290 (NH), 1650–1700 (C‚O),
1540–1590 (Aromatic). 1H NMR (CDCl3): 9.41 (bs, 1H,
NH); 8.85 (bs, 1H, NH); 7.10–7.65 (m, 7H, Ar); 3.82 (bs,
4H, piperazine-H); 3.42 (s, 2H, CH2); 2.76 (bs, 4H, pipera-
zine-H). 13C NMR (CDCl3): 170.8, 168.9, 155.7, 152.6,
131.4, 128.0, 126.1, 122.4, 121.7, 120.8, 119.3, 117.3, 112.3,
60.2, 52.8, 48.3. LC/MS m/z, calcd for C18H19N5O2S2
[M+H]+, 402; found, 402.
5.4. N0-acetyl-2-(4-(benzo[d]thiazol-2-yl)piperazin-1-yl)-
acetohydrazide (5d)
The title compound was prepared from compound 4 (0.291 g,
1.0 mmol) and acetyl chloride (0.126 g, 1.6 mmol) according to
the procedure A (time = 4 days). Yield: 0.070 g (21%), as a
white powder. mp 230–232 C (dec.). Procedure B (time = 30 -
min): Yield: 0.273 g (82%). IR; mmax (KBr) cm
1: 3130–3300
(NH), 1650–1700 (C‚O), 1540–1600 (Aromatic). 1H NMR
(CDCl3): 9.32 (bs, 1H, NH); 8.30 (bs, 1H, NH); 7.63(d,
J= 7.50 Hz, 1H, Ar); 7.52 (d, J= 7.5 Hz, 1H, Ar); 7.31
(t, J= 8.0 Hz, 1H, Ar); 7.11 (t, J= 8.0 Hz, 1H, Ar); 3.80
(t, J= 8.0 Hz, 4H, piperazine-H); 3.20 (s, 2H, CH2); 2.70 (t,
J= 5.00 Hz, 4H, piperazine-H); 2.02 (s, 3H, CH3).
13C
NMR (CDCl3): 168.6, 167.5, 165.1, 152.6, 130.8, 126.1,
121.7, 120.8, 119.3, 60.5, 52.8, 48.3, 20.8. LC/MS m/z, calcd
for C15H19N5O2S [M+H]
+, 334; found, 334.
5.5. N0-(2-(4-(benzo[d]thiazol-2-yl)piperazin-1-yl)acetyl)-2-
chloronicotinohydrazide (5e)
The title compound was prepared from compound 4 (0.291 g,
1.0 mmol) and 2-chloropyridine-3-carbonyl chloride (0.282 g,
1.6 mmol) according to the procedure A (time = 6 days).
Yield: 0.181 g (42%), as a pale yellow powder. mp 223–
226 C (dec.). Procedure B (time = 30 min): Yield: 0.304 g
(92%). IR; mmax (KBr) cm
1: 3100–3350 (NH), 1650–1690
(C‚O), 1550–1600 (Aromatic). 1H NMR (CDCl3): 9.60 (bs,
1H, NH); 9.27 (bs, 1H, NH); 8.61–7.12 (m, 7H, Ar); 3.78
(bs, 4H, piperazine-H); 3.31 (s, 2H, CH2); 2.70 (bs, 4H, piper-
azine-H). 13C NMR (CDCl3): 169.2, 168.5, 166.7, 161.5, 151.9,
147.6, 140.3, 140.2, 128.3, 126.1, 122.8, 121.8, 120.8, 119.3,
60.3, 52.4, 48.2. LC/MS m/z, calcd for C19H19N6O2S
[M+H]+, 431; found, 431.
5.6. N0-(2-(4-(benzo[d]thiazol-2-yl)piperazin-1-yl)acetyl)-
pyrrolidine-2-carbohydrazide (5f)
The title compound was prepared from compound 4 (0.291 g,
1.0 mmol) and pyrrolidine-2-carbonyl chloride (0.214 g,
1.6 mmol) according to the procedure A (time = 5 days).
Yield: 0.105 g (27%), as a yellow powder. mp 120–123 C(dec.). Procedure B (time = 30 min): Yield: 0.314 g (81%).
IR; mmax (KBr) cm
1: 3100–3350 (NH), 1640–1700 (C‚O),
1540–1600 (Aromatic). 1H NMR (CDCl3): 8.85 (bs, 1H,
NH); 7.62 (d, J= 4.50 Hz, 1H, Ar); 7.57 (d, J = 4.50 Hz,
1H, Ar); 7.32 (t, J = 8.00 Hz, 1H, Ar); 7.10 (t, J= 8.00 Hz,
1H, Ar); 6.82 (bs, 1H, NH); 3.75 (bs, 4H, piperazine-H);
3.45 (bs, 4H, pyrrole); 3.30 (s, 2H, CH2); 2.81 (bs, 4H, pipera-
zine-H); 1.95 (bs, 1H, NH pyrrole); 1.95 (bs, 3H, pyrrole). 13C
NMR (CDCl3): 168.8, 168.6, 155.6, 152.6, 130.8, 126.0, 121.6,
120.8, 119.2, 60.6, 52.7, 48.3, 47.1, 45.7, 25.4. LC/MS m/z,
calcd for C18H24N6O2S [M+H]
+, 389; found, 389.
5.7. N0-(2-(4-(benzo[d]thiazol-2-yl)piperazin-1-yl)acetyl)-
piperidine-4-carbohydrazide (5g)
The title compound was prepared from compound 4 (0.291 g,
1.0 mmol) and piperidine-4-carbonyl chloride (0.236 g,
1.6 mmol) according to the procedure A (time = 7 days).
Yield: 0.113 g (28%), as a white powder. mp 139–142 C
(dec.). Procedure B (time = 30 min): Yield: 0.342 g (85%).
IR; mmax (KBr) cm
1: 3100–3300 (NH), 1650–1690 (C‚O),
1540–1590 (Aromatic). 1H NMR (CDCl3): 8.92 (bs, 1H,
NH); 7.68 (d, J= 4.50 Hz, 1H, Ar); 7.58 (d, J = 4.50 Hz,
1H, Ar); 7.35 (t, J = 8.00 Hz, 1H, Ar); 7.13 (t, J= 8.00 Hz,
1H, Ar); 6.98 (bs, 1H, NH); 3.75 (bs, 4H, piperazine-H);
3.72 (bs, 4H, piperidine); 3.44 (bs, 4H, piperidine); 3.23 (s,
2H, CH2); 2.78 (bs, 4H, piperazine-H); 1.83(m, 6H, piperi-
dine). 13C NMR (CDCl3): 168.6, 168.0, 158.2, 156.3, 130.8,
126.0, 121.6, 120.7, 119.2, 60.6, 52.8, 48.9, 44.9, 25.3, 24.2.
LC/MS m/z, calcd for C19H26N6O2S [M+H]
+, 403; found,
403.
5.8. N0-(2-(4-(benzo[d]thiazol-2-yl)piperazin-1-yl)acetyl)-
furan-2-carbohydrazide (5h)
The title compound was prepared from compound 4 (0.291 g,
1.0 mmol) and furan-2-carbonyl chloride (0.209 g, 1.6 mmol)
according to the procedure A (time = 3 days). Yield: 0.166 g
(43%), as a yellow powder. mp 107–110 C (dec.). Procedure
B (time = 30 min): Yield: 0.358 g (93%). IR; mmax (KBr) cm
1: 3100–3290 (NH), 1650–1700 (C‚O), 1540–1600 (Aro-
matic). 1H NMR (CDCl3): 9.34 (bs, 1H, NH); 8.86 (bs, 1H,
NH); 7.67–6.57 (m, 7H, Ar); 3.78 (bs, 4H, piperazine-H);
3.31 (s, 2H, CH2); 2.78 (bs, 4H, piperazine-H).
13C NMR
(CDCl3): 168.6, 167.7, 156.1, 152.0, 145.6, 145.0, 130.8,
126.1, 121.7, 120.8, 119.3, 116.2, 112.3, 60.5, 52.8, 48.3. LC/
MS m/z, calcd for C18H19N5O3S [M+H]
+, 386; found, 386.
5.9. N0-(2-(4-(benzo[d]thiazol-2-yl)piperazin-1-yl)acetyl)-2-
methylbenzohydrazide (5i)
The title compound was prepared from compound 4 (0.291 g,
1.0 mmol) and 2-methylbenzoyl chloride (0.247 g, 1.6 mmol)
according to the procedure A (time = 4 days). Yield: 0.041 g
(10%), as a white powder. mp 198–201 C (dec.). Procedure
B (time = 30 min): Yield: 0.315 g (77%). IR; mmax (KBr) cm
1: 3100–3250 (NH), 1650–1690 (C‚O), 1540–1610 (Aro-
matic). 1H NMR (CDCl3): 9.32 (bs, 1H, NH); 8.58 (bs, 1H,
NH); 7.70–7.12 (m, 8H, Ar); 3.80 (bs, 4H, piperazine-H);
3.32 (s, 2H, CH2); 2.81 (bs, 4H, piperazine-H); 2.52 (s, 3H,
CH3).
13C NMR (CDCl3): 169.0, 167.1, 156.1, 137.4, 132.4,
132.0, 131.4, 131.1, 127.4, 127.3, 126.2, 125.9, 121.8, 120.8,
S930 M. Al-Talib et al.119.3, 67.1, 60.4, 52.8, 48.3, 19.9. LC/MS m/z, calcd for
C21H23N5O3S [M+H]
+, 410; found, 410.
5.10. N0-(2-(4-(benzo[d]thiazol-2-yl)piperazin-1-yl)acetyl)-
1,3-dihydroisobenzofuran-5-carbohydrazide (5j)
The title compound was prepared from compound 4 (0.291 g,
1.0 mmol) and benzo[d][1,3]dioxole-5-carbonyl chloride
(0.247 g, 1.6 mmol) according to the procedure A (time =
6 days). Yield: 0.176 g (40%), as a yellow powder. mp 118–
120 C (dec.). Procedure B (time = 30 min): Yield: 0.395 g
(90%). IR; mmax (KBr) cm
1: 3090–3300 (NH), 1650–1700
(C‚O), 1540–1600 (Aromatic). 1H NMR (CDCl3): 9.45 (bs,
1H, NH); 8.95 (bs, 1H, NH); 7.73–6.73 (m, 7H, Ar); 6.04 (s,
2H, CH2-dioxole); 3.81 (bs,4H, piperazine-H); 3.31 (s, 2H,
CH2); 2.77 (bs, 4H, piperazine-H).
13C NMR (CDCl3):
169.6, 167.3, 164.3, 152.5, 151.2, 148.1, 130.7, 126.1, 125.3,
122.3, 121.7, 120.7, 119.3, 109.9, 107.7, 101.8, 60.6, 52.9,
48.3. LC/MS m/z, calcd for C21H21N5O4S [M+H]
+, 440;
found, 440.Acknowledgments
Dr. Al-Talib is grateful to the Dean of Research and Graduate
studies at the Yarmouk University for ﬁnancial support
(Project 35/2009).
Dr. Al-Soud is grateful to the Deanship of Academic Research
of the University of Al al-Bayt.References
Al-Soud, Y.A., Al- Sa’doni, H., Amajaour, H.A.S., Al-Masoudi, N.A.,
2007. Z. Naturforsch. 62b, 523–528.Al-Soud, Y.A., Al- Sa’doni, H., Amajaour, H.A.S., Salih, K.S.M.,
Mubarak, M.S., Al-Masoudi, N.A., Jaber, I.H., 2008a. Z. Natur-
forsch. 63b, 83–89.
Al-Soud, Y.A., Al-Sa’doni, H., Saeed, B., Jaber, I.H., Beni-Khalid,
M.O., Al-Masoudi, N.A., Abdul-kadir, T., La Colla, P., Burson-
era, B., Sanna, T., Loddo, R., 2008b. Arkivoc x, 225–238.
Al-Soud, Y.A., Al- Sa’doni, H., Saber, S.O.W., Al-Shaneek, R.H.M.,
Al-Masoudi, N.A., Loddo, R., La Colla, P., 2010. Z. Naturforsch.
65b, 1372–1380.
Baell, J.B., Forsyth, S.A., Gable, R.W., Norton, R.S., Mulder, R.J.J.,
2002. Comput. Aided Mol. Des. 15, 1119–1136.
Ban, M., Taguchi, H., Katsushima, T., Takahashi, M., Shinoda, K.,
Watanabe, A., Tominaga, T., 1998. Bioorg. Med. Chem 6, 1069–
1076.
Bradshaw, T.D., Westwell, A.D., 2004. Curr. Med. Chem. 11, 1241–
1253.
Choi, S.J., Park, H.J., Lee, S.K., Kim, S.W., Han, G., Choo, H.Y.P.,
2006. Bioorg. Med. Chem. 14, 1229–1235.
Chung, Y., Shin, Y.-K., Zhan, C.-G., Lee, S., Cho, H., 2004. Arch.
Pharmacal Res. 27, 893–900.
Esteves-Souza, A., Pissinate, K., Nascimento, G.M., Grynberg, N.F.,
Aurea, E., 2006. Bioorg. Med. Chem. 14, 492–499.
Mc Fadyen, M.C.E., Melvin, W.T., Murray, G.I., 2004. Mol. Cancer
Ther. 3, 363–371.
Papadopoulou, C., Geronikaki, A., Hadjipavlou-Litina, D., 2005.
Farmaco 60, 969–973.
Racane, L., Tralic-Kulenovic, V., Fiser-Jakic, L., Boykin, D.W.,
Karminski-Zamola, G., 2001. Heterocycles 55, 2085–2098.
Starcevic, K., Caleta, I., Cincic, D., Kaitner, B., Kralj, M., Ester, K.,
Karminski-Zamola, G., 2006. Heterocycles 68, 2285–2299.
Westway, S.M., Thompson, M., Rami, H.K., Stemp, G., Trouw, L.S.,
Mitchell, D.J., Seal, J.T., Medhurst, S.J., Lappin, S.C., Biggs, J.,
Wright, J., Arpino, S., Jerman, J.C., Cryan, J.E., Holland, V.,
Winborn, K.Y., Coleman, T., Stevens, A.J., Davis, J.B., Gun-
thorpe, M.J., 2008. Bioorg. Med. Chem. Lett. 18, 5609–5613.
Yoshida, M., Hayakawa, I., Hayashi, N., Agatsuma, T., Oda, Y.,
Tanzawa, F., Iwasaki, S., Koyama, K., Furukawa, H., Kurakata,
S., 2005. Bioorg. Med. Chem. Lett. 15, 3328–3332.
